{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:43:20Z","timestamp":1694756600569},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:00:00Z","timestamp":1470787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005969","name":"Universit\u00e0 di Bologna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis (MF) is the most severe among the classical Philadelphia\u2010negative myeloproliferative neoplasms that also include essential thrombocytemia and polycythemia vera. Myelofibrosis is characterized by numerous genetic lesions, often variously associated with each other, and by an aggressive clinical phenotype leading to severely reduced survival. Also, the inflammatory microenvironment plays a key role in disease initiation and progression. Because of the complexity of its pathogenesis and the variability of clinical features, MF is a disease that requires a personalized approach and remains orphan of curative treatments besides allogeneic transplantation. JAK2 inhibitors have marked a remarkable progress, because they alleviate systemic symptoms and reduce splenomegaly but have a limited effect on survival, on mutation load, and on marrow fibrosis. Here, we review the main contributing factors to MF pathogenesis and prognosis, focusing on how these factors relate to therapeutic choices. We discuss results from ongoing studies of JAK2 inhibitors and report on new therapeutic strategies that proved effective in early preclinical and clinical trials, including combination treatments, antifibrotic agents, and telomerase inhibitors.<\/jats:p>","DOI":"10.1002\/hon.2324","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T03:36:42Z","timestamp":1470886602000},"page":"145-150","source":"Crossref","is-referenced-by-count":2,"title":["New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment"],"prefix":"10.1002","volume":"35","author":[{"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Institute of Hematology \u201cL. and A. Ser\u00e0gnoli\u201d  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Auteri","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Institute of Hematology \u201cL. and A. Ser\u00e0gnoli\u201d  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. and A. Ser\u00e0gnoli\u201d Sant'Orsola\u2010Malpighi University Hospital  Via Massarenti 9 40138 Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,10]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.024"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24440"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238956"},{"key":"e_1_2_4_6_1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood.V120.21.1734.1734","article-title":"Comorbidity burden in elderly persons with non\u2010CML myeloproliferative neoplasms: real\u2010world evidence from a United States Medicare Population","volume":"120","author":"Davis KL","year":"2012","journal-title":"Blood"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09107.x"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_4_12_1","doi-asserted-by":"crossref","unstructured":"NangaliaJ Green T.R.The evolving genomic landscape of myeloproliferative neoplasms.American Society of Hematology. Education Program pp.287\u2013296(2014).","DOI":"10.1182\/asheducation-2014.1.287"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-292102"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.020"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.374"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539098"},{"key":"e_1_2_4_21_1","unstructured":"VannucchiAM GuglielmelliP RotunnoGet al.Mutation\u2010Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG\u2010MRT project.ASH:Oral and Poster Abstracts session 634 (2014)."},{"key":"e_1_2_4_22_1","doi-asserted-by":"crossref","unstructured":"TefferiA GuglielmelliP FinkeC et al.Integration of mutations and karyotype towards a Genetics\u2010Based Prognostic Scoring System (GPSS) for primary myelofibrosis.ASH:Oral and Poster Abstracts.Session 634 (2014).","DOI":"10.1182\/blood.V124.21.406.406"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.6"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/32934"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.07.011"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08266.x"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12220"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0862"},{"issue":"21","key":"e_1_2_4_34_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V124.21.712.712","article-title":"Phase 1b dose\u2010escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis","volume":"124","author":"Gupta V","year":"2014","journal-title":"Blood"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01279.x"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503479"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_4_38_1","doi-asserted-by":"crossref","unstructured":"VerstovsekS MesaRA FoltzLMet al.PRM\u2010151 in myelofibrosis: durable efficacy and safety at 72\u00a0weeks.ASH:Oral and Poster Abstracts. Session: 634 (2015).","DOI":"10.1182\/blood.V126.23.56.56"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2324","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:13:05Z","timestamp":1694686385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,10]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/hon.2324"],"URL":"https:\/\/doi.org\/10.1002\/hon.2324","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,10]]}}}